Drug Profile
Faricimab - Roche
Alternative Names: Faricimab-svoa; RG 7716; RO 6867461; VABYSMO; VabysmoLatest Information Update: 08 Feb 2024
Price :
$50
*
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Genentech; Roche
- Class Bispecific antibodies; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
- Preregistration Diabetic retinopathy
- Phase III Angioid streaks
- Clinical Phase Unknown Polypoidal choroidal vasculopathy
Most Recent Events
- 01 Feb 2024 Efficacy data from the phase III BALATON trial in Retinal oedema released by Roche
- 01 Feb 2024 Efficacy data from the phase III COMINO trial in Diabetic macular oedema and Retinal oedema released by Roche
- 01 Feb 2024 Efficacy and adverse event data from the phase III BALATON and COMINO trials in Macular and Retinal oedema released by Genentech